<DOC>
	<DOCNO>NCT00493285</DOCNO>
	<brief_summary>The overall objective MEDI-534 clinical development program evaluate safety , efficacy tolerability MEDI-534 prevention serious RSV PIV3 disease young infant .</brief_summary>
	<brief_title>Safety Tolerability Study Evaluate MEDI-534 Children 6 &lt; 24 Months Age</brief_title>
	<detailed_description>The primary objective study describe safety tolerability multiple dose MEDI-534 10^4 , 10^5 , 10^6 TCID50 administer RSV PIV3 seronegative child 6 &lt; 24 month age .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Paramyxoviridae Infections</mesh_term>
	<criteria>Male female whose age day randomization 6 &lt; 24 month ( reach 6th month birthday yet reach 2nd year birthday ) Subject seronegative RSV PIV3 screen Subject product normal full term pregnancy ( define &gt; 36 week gestation ) Subject general good health Subject 's legal representative available telephone Written inform consent HIPAA authorization ( applicable ) obtain subject 's legal representative Subject 's legal representative able understand comply requirement protocol judge investigator Subject available complete followup period , end RSV season ( provisionally define 01/Apr United States ) 180 day final dose study vaccine , whichever later Subject 's legal representative must willing able bring subject study site evaluation respiratory illness accordance protocol Any fever ( equal great 100.4°F [ equal great 38.0°C ] , regardless route ) low respiratory illness ( Section 4.1.2 ) within 7 day prior randomization Moderate severe nasal congestion investigator 's opinion could prevent intranasal delivery vaccine Any drug therapy ( chronic ) within 7 day prior randomization expect receipt protocolspecified blood collection 28 day study vaccine dosing , except infrequent use overthecounter medication pain reliever permit accord judgment investigator Any current expect receipt immunosuppressive agent include steroid ( 2 mg/kg per day prednisone equivalent , equal great 20 mg/day subject weigh &gt; 10 kg , give daily alternate day equal great 14 day ) ; child category receive study vaccine immunosuppressive agent include corticosteroid therapy discontinue equal great 30 day ; use topical steroid permit accord judgment investigator History receipt blood transfusion expect receipt 30 day follow final study vaccine dose History receipt immunoglobulin product expect receipt 30 day study vaccine dose Receipt investigational drug within 60 day prior randomization expect receipt 30 day final study vaccine dose Receipt live virus vaccine ( exclude rotavirus vaccine ) within 28 day prior randomization expect receipt within 28day window around study vaccine dose Receipt inactivate ( i.e. , nonlive ) vaccine rotavirus vaccine within 14 day prior randomization expect receipt within 14day window around study vaccine dose Known suspect immunodeficiency , include HIV Living home enrol classroom day care infant &lt; 24 month age ( one child per household may enrol study ) Contact pregnant caregiver A household contact immunocompromised ; subject also avoid close contact immunocompromised individual least 30 day study vaccine dose A household contact health care provider contact immunocompromised patient day care provider infant age 6 month History allergic reaction component study vaccine Previous medical history , evidence , intercurrent chronic illness , opinion investigator , may compromise safety subject Known suspect active chronic hepatitis infection History medical diagnosis asthma , reactive airway disease , wheeze require medication , cystic fibrosis , bronchopulmonary dysplasia , chronic pulmonary disease , medically confirm apnea , hospitalization respiratory illness mechanical ventilation Family member household contact employee research center otherwise involved conduct study Any condition , opinion investigator , might interfere study vaccine evaluation</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Lower Respiratory Tract Illness</keyword>
	<keyword>RSV PIV3 infection</keyword>
</DOC>